Effect of APOE Genotype on Amyloid Deposition, Brain Volume, and Memory in Cognitively Normal Older Individuals

Journal of Alzheimer's Disease

Volumn 58, Issue 4, 2017, Pages 1293-1302

  Lim, Yen Ying ^a   Williamson, Robert ^a   Laws, Simon M ^b,c,d   Villemagne, Victor L ^a,f   Bourgeat, Pierrick ^e   Fowler, Christopher ^a   Rainey Smith, Stephanie ^b   Salvado, Olivier ^e   Martins, Ralph N ^b   Rowe, Christopher C ^a,f   Masters, Colin L ^a   Maruff, Paul ^a,g   Chambers, Brian ^h   Chiu, Edmond ^h   Clarnette, Roger ^h   Darby, David ^h   Davison, Mary ^h   Drago, John ^h   Drysdale, Peter ^h   Gilbert, Jacqueline ^h   Lim, Kwang ^h   Lautenschlager, Nicola ^h   LoGiudice, Dina ^h   McCardle, Peter ^h   McFarlane, Steve ^h   Mander, Alastair ^h   Merory, John ^h   O'Connor, Daniel ^h   Scholes, Ron ^h   Samuel, Mathew ^h   Trivedi, Darshan ^h   Woodward, Michael ^h   more..

^a UNIVERSITY OF MELBOURNE   (Australia)

^b EDITH COWAN UNIVERSITY   (Australia)

^c Co operative Research Centre for Mental Health ^*  (Australia)

^d CURTIN UNIVERSITY   (Australia)

^e CSIRO   (Australia)

^f AUSTIN HEALTH   (Australia)

^g Scientific Division   (Australia)

^h NONE

Author keywords

Alzheimer's disease; amyloid; apolipoprotein E; hippocampal volume; memory; mild cognitive impairment

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; APOLIPOPROTEIN E;

ADULT; AGING; ALLELE; ALZHEIMER DISEASE; ARTICLE; BRAIN SIZE; BRAIN TOMOGRAPHY; COGNITION; COMPARATIVE STUDY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; EPISODIC MEMORY; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HETEROZYGOTE; HIPPOCAMPUS; HOMOZYGOTE; HUMAN; MALE; MEMORY ASSESSMENT; MOLECULAR PATHOLOGY; NEUROIMAGING; NEUROPATHOLOGY; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; AGED; ANALYSIS OF VARIANCE; AUSTRALIA; DIAGNOSTIC IMAGING; GENETICS; MEMORY; METABOLISM; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; PHYSIOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AMYLOID BETA-PEPTIDES; ANALYSIS OF VARIANCE; APOLIPOPROTEINS E; AUSTRALIA; COGNITION; CROSS-SECTIONAL STUDIES; FEMALE; GENOTYPE; HIPPOCAMPUS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MEMORY; MEMORY, EPISODIC; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; POSITRON-EMISSION TOMOGRAPHY;

EID: 85021257552     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-170072     Document Type: Article

References (41)

1. Roses AD (2006) On the discovery of the genetic association of Apolipoprotein E genotypes and common late-onset Alzheimer disease. J Alzheimers Dis 9, 361-366.
2. Caselli RJ, Dueck AC, Osborne D, Sabbagh MN, Connor DJ, Ahern GL, Baxter LC, Rapcsak SZ, Shi J, Woodruff BK, Locke DEC, Snyder CH, Alexander GE, Rademakers R, ReimanEM(2009) Longitudinal modeling of age-related memory decline and the APOE ϵ4 effect. New Engl J Med 361, 255-263.
3. Lim YY, Villemagne VL, Pietrzak RH, Ames D, Ellis KA, Harrington K, Snyder PJ, Martins RN, Masters CL, Rowe CC, Maruff P (2015) APOE ϵ4 moderates amyloid-related memory decline in preclinical Alzheimer's disease. Neurobiol Aging 36, 1239-1244.
4. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, Myers RH, Pericak-Vance MA, Risch N, van Duijn CM (1997) Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. J Amer Med Assoc 278, 1349-1356.
5. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261, 921-923.
6. Ossenkoppele R, Jansen WJ, Rabinovici GD, Knol DL, van der Flier WM, van Berckel BN, Scheltens P, Visser PJ, Group APS, Verfaillie SC, Zwan MD, Adriaanse SM, Lammertsma AA, Barkhof F, Jagust WJ, Miller BL, Rosen HJ, Landau SM, Villemagne VL, Rowe CC, Lee DY, Na DL, Seo SW, Sarazin M, Roe CM, Sabri O, Barthel H, Koglin N, Hodges J, Leyton CE, Vandenberghe R, van Laere K, Drzezga A, Forster S, Grimmer T, Sánchez-Juan P, Carril JM, Mok V, Camus V, Klunk WE, Cohen AD, Meyer PT, Hellwig S, Newberg A, Frederiksen KS, Fleisher AS, Mintun MA,Wolk DA, Nordberg A, Rinne JO, Chételat G, Lleo A, Blesa R, Fortea J, Madsen K, Rodrigue KM, Brooks DJ (2015) Prevalence of amyloid PET positivity in dementia syndromes: A meta-analysis. J Amer Med Assoc 313, 1939-1949.
7. Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, Jones G, Fripp J, Tochon-Danguy H, Morandeau L, O'Keefe G, Price R, Raniga P, Robins P, Acosta O, Lenzo N, Szoeke C, Salvado O, Head R, Martins RM, C.L., Ames D, Villemagne V (2010) Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 31, 1275-1283.
8. Petersen RC, Wiste HJ, Weigand SD, Rocca WA, Roberts RO, Mielke MM, Lowe VJ, Knopman DS, Pankratz VS, Machulda MM, Geda YE, Jack CRJ (2016) Association of elevated amyloid levels with cognition and biomarkers in cognitively normal people from the community. JAMA Neurol 73, 85-92.
9. Liu CC, Kanekiyo T, Xu H, Bu G (2013) Apolipoprotein E and Alzheimer disease: Risk, mechanisms and therapy. Nat Rev Neurol 9, 106-118.
10. Yu JT, Tan L, Hardy J (2014) Apolipoprotein E in Alzheimer's disease: An update. Ann Rev Neuroscl 37, 79.
11. LimYY, Ellis KA, Ames D, Darby D, Harrington K, Martins RN, Masters CL, Rowe C, Savage G, Szoeke C, Villemagne VL, Maruff P, AIBL Research Group (2013) Aβ amyloid, cognition and APOE genotype in healthy older adults. Alzheimers Dement 9, 538-545.
12. Kantarci K, Lowe V, Przybelski SA, Weigand SD, Senjem ML, Ivnik RJ, Preboske GM, Roberts R, Geda YE, Boeve BF, Knopman DS, Petersen RC, Jack CR (2012) APOE modifies the association between Aβ load and cognition in cognitively normal older adults. Neurology 78, 232-240.
13. Ellis KA, Bush AI, Darby D, De Fazio D, Foster J, Hudson P, Lautenschlager NT, Lenzo N, Martins RN, Maruff P, Masters C, Milner A, Pike K, Rowe C, Savage G, Szoeke C, Taddei K, Villemagne V, Woodward M, Ames D, AIBL Research Group (2009) The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: Methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease. Int Psychogeriatr 21, 672-687.
14. Wong DF, Rosenberg PB, Zhou Y, Kumar A, Raymont V, Ravert HT, Dannals RF, Nandi A, Brasić JR, Ye W, Hilton J, Lyketsos C, Kung HF, Joshi AD, Skovronsky DM, Pontecorvo MJ (2010) In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). J Nucl Med 51, 913-920.
15. Vandenberghe R,Van Laere K, Ivanoiu A, Salmon E, Bastin C, Triau E, Hasselbalch S, Law I, Andersen A, Korner A, Minthon L, Garraux G, Nelissen N, Bormans G, Buckley C, Owenius R, Thurfjell L, Farrar G, Brooks DJ (2010) 18Fflutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial. Ann Neurol 68, 319-329.
16. Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, Mintun MA, Pontecorvo MJ, Hefti F, Carpenter AP, Flitter ML, Krautkramer MJ,Kung HF, Coleman RE, Doraiswamy PM, Fleisher AS, Sabbagh MN, Sadowsky CH, Reiman EP, Zehntner SP, Skovronsky DM, AV45-A07 Study Group (2011) Use of florbetapir-PET for imaging beta-amyloid pathology. J Amer Med Assoc 305, 275-283.
17. Villemagne VL, Doré V, Yates P, Brown B, Mulligan R, Bourgeat P, Veljanoski R, Rainey-Smith SR, Ong K, Rembach A, Williams R, Burnham SC, Laws SM, Salvado O, Taddei K, Macaulay SL, Martins RN, Ames D, Masters CL, RoweCC(2014) En attendant centiloid. Adv Res 2, 723-729.
18. Collins DL, ZijdenbosAP,KollokianV, Sled JG, Kabani NJ, Holmes CJ, Evans AC (1998) Design and construction of a realistic digital brain phantom. IEEE Trans Med Imaging 17, 463-468.
19. Acosta O, Bourgeat P, Zuluaga MA, Fripp J, Salvado O, Ourselin S, Alzheimer's Disease Neuroimaging Initiative (2009) Automated voxel-based 3D cortical thickness measurement in a combined Lagrangian-Eulerian PDE approach using partial volume maps. Med Image Anal 13, 730-743.
20. Boccardi M, Bocchetta M, Apostolova LG, Barnes J, Bartzokis G, Corbetta G, DeCarli C, deToledo-Morrell L, Firbank M, Ganzola R, Gerritsen L, Henneman W, Killiany RJ, Malykhin N, Pasqualetti P, Pruessner JC, Redolfi A, Robitaille N, Soininen H, Tolomeo D, Wang L, Watson C, Wolf H, Duvernoy H, Duchesne S, Jack CR, Frisoni GB, EADC-ADNI Working Group on the Harmonized Protocol for Manual Hippocampal Segmentation (2015) Delphi definition of the EADC-ADNI Harmonized Protocol for hippocampal segmentation on magnetic resonance. Alzheimers Dement 11, 126-138.
21. LimYY,Maruff P, Pietrzak RH, Ames D, Ellis KA, Harrington K, Lautenschlager NT, Szoeke C, Martins RN, Masters CL, Villemagne VL, Rowe CC, AIBL Research Group (2014) Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease. Brain 137, 221-231.
22. Rowe CC, Ackermann U, BrowneW, Mulligan R, Pike KL, O'Keefe G, Tochon-Danguy H, Chan G, Berlangieri SU, Jones G, Dickinson-Rowe KL, Kung HP, Zhang W, Kung MP, Skovronsky D, Dyrks T, Holl G, Krause S, Friebe M, Lehman L, Lindemann S, Dinkelborg LM, Masters CL, VillemagneVL(2008) Imaging of amyloid β in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: Proof of mechanism. Lancet Neurol 7, 129-135.
23. Thai C, Lim YY, Villemagne VL, Laws SM, Ames D, Ellis KA, Rainey-Smith SR, Martins RN, Masters CL, Rowe CC, Maruff P, AIBL Research Group (2015) Amyloid-related memory decline in preclinical Alzheimer's disease is dependent on APOE ϵ4 and is detectable over 18-months. PLoS One 10, e0139082.
24. Villemagne VL, Pike KE, Chételat G, Ellis KA, Mulligan RS, Bourgeat P, Ackermann U, Jones G, Szoeke C, Salvado O, Martins R, O'Keefe G, Mathis CA, Klunk WE, Ames D, Masters CL, Rowe CC (2011) Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease. Ann Neurol 69, 181-192.
25. Lim YY, Laws SM, Villemagne VL, Pietrzak RH, Porter T, Ames D, Fowler C, Rainey-Smith S, Martins RN, Salvado O, Bourgeat P, Rowe CC, Masters CL, Maruff P (2016) Aβ-related memory decline in APOE ϵ4 non-carriers: Implications for Alzheimer's disease. Neurology 86, 1635-1642.
26. Reiter K, Nielson KA, Durgerian S,Woodard JL, Smith JC, Seidenberg M, Kelly DA, Rao SM (2017) Five-year longitudinal brain volume change in healthy elders at genetic risk for Alzheimer's disease. J Alzheimers Dis 55, 1363-1377.
27. Dowell NG, Evans SL, Tofts PS, King SL, Tabet N, Rusted JM (2016) Structural and resting-state MRI detects regional brain differences in young and mid-age healthy APOEe4 carriers compared with non-APOE-e4 carriers. NMR Biomed 29, 614-624.
28. Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, Szoeke C, Macaulay SL, Martins R, Maruff P, Ames D, Rowe CC, Masters CL, AIBL Research Group (2013) Amyloid β deposition, neurodegeneration and cognitive decline in sporadic Alzheimer's disease: A prospective cohort study. Lancet Neurol 12, 357-367.
29. Jack CR, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, Shaw LM, Vemuri P, Wiste HJ, Weigand SD, Lesnick TG, Pankratz VS, Donohue MC, Trojanowski JQ (2013) Tracking pathophysiological processes in Alzheimer's disease: An updated hypothetical model of dynamic biomarkers. Lancet Neurol 12, 207-216.
30. Bennett DA, Schneider JA, Wilson RS, Bienias JL, Arnold SE (2004) Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function. Arch Neurol 61, 378-384.
31. Ingelsson M, Fukumoto H, Newell KL, Growdon JH, Hedley-Whyte ET, Frosch MP, Albert MS, Hyman BT, Irizarry MC (2004) Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle formation inADbrain. Neurology 62, 925-931.
32. Giannakopoulos P, Herrmann FR, Bussière T, Bouras C, Kövari E, Perl DP, Morrison JH, Gold G, Hof PR (2003) Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease. Neurology 60, 1495-1500.
33. Ashford JW (2004) APOE genotype effects on Alzheimer's disease: Onset and epidemiology. J Mol Neurosci 23, 157-165.
34. Raber J, Huang Y, Ashford JW (2004) APOE genotype accounts for the vast majority ofADrisk andADpathology. Neurobiol Aging 25, 641-650.
35. Kanekiyo T, Xu H, Bu G (2014) ApoE and Aβ in Alzheimer's disease: Accidental encounters or partners? Neuron 81, 740-754.
36. Yu L, Boyle PA, Leurgans S, Schneider JA, Bennett DA (2014) Disentangling the effects of age and APOE on neuropathology and late life cognitive decline. Neurobiol Aging 35, 819-826.
37. Monsell SE, Kukull WA, Roher AE, Maarouf CL, Serrano G, Beach TG, Caselli RJ, Montine TJ, Reiman EM (2015) Characterizing apolipoprotein E ϵ4 carriers and noncarriers with the clinical diagnosis of mild to moderate Alzheimer dementia and minimal β-amyloid peptide plaques. JAMA Neurol 72, 1124-1131.
38. Conejero-Goldberg C, Gomar JJ, Bobes-Bascaran T, Hyde TM, Kleinman JE, Herman MM, Chen S, Davies P, Goldberg TE (2014) APOE2 enhances neuroprotection against Alzheimer's disease through multiple molecular mechanisms. Mol Psychiatr 19, 1243-1250.
39. Shinohara M, Kanekiyo T, Yang L, Linthicum D, Shinohara M, Fu Y, Price L, Frisch-Daiello JL, Han X, Fryer JD, Bu G (2016) APOE2 eases cognitive decline during aging: Clinical and preclinical evaluations. Ann Neurol. doi: 10.1002/ana.24628
40. Reiman EM, Langbaum JB, Fleisher AS, Caselli RJ, Chen K, Ayutyanont N, Quiroz YT, Kosik KS, Lopera F, Tariot PN (2011) Alzheimer's Prevention Initiative: A plan to accelerate the evaluation of presymptomatic treatments. J Alzheimers Dis 26, 321-329.
41. Roses AD, Saunders AM, Lutz MW, Zhang N, Hariri AR, Asin KE, Crenshaw DG, Budur K, Burns DK, Brannan SK (2014) New applications of disease genetics and pharmacogenetics to drug development. Curr Opin Pharmacol 14, 81-89.